This recording will provide a comprehensive update on the current standards and innovations in Von Hippel-Lindau (VHL) care, focusing on practical decision-making across specialties.
VHL syndrome presents unique challenges in clinical management due to its multisystem involvement and hereditary nature. With recent advances in surgical techniques, radiotherapy, and targeted systemic therapies such as HIF-2α inhibitors, the treatment landscape is rapidly evolving.
Speakers:
- Dr. A. Larcher (IT)
- Drs. L. Salerno (IT)
- Dr. P.J. Zondervan (NL)
- Drs. M. Soleimani (CA)
This recording is brought to you in collaboration with the EAU Section of Oncological Urology.
Acknowledgment This activity is supported by an educational grant from our industry partner – MSD, with no involvement in the programme or speaker selection: https://www.msd.com/